Good morning and welcome to the Olin Corporation Fourth Quarter and Full Year 2018 Earnings Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Larry Kromidas, Olin's Director of Investor Relations. Please go ahead, sir.

Thank you, Cole. Good morning, everyone, and thank you for joining us on our fourth quarter and full year 2018 earnings call. Before we begin this morning, I want to remind everyone that this presentation along with the associated slides and the question-and-answer session following our prepared remarks will include statements regarding estimates of future performance. Please note that these are forward-looking statements and that actual results could differ materially from those projected. Some factors that could cause actual results to differ from our projections are described without limitations in the Risk Factors section of our most recent Form 10-K and in yesterday's fourth quarter earnings press release. A copy of today's transcript and slides will be available on our website in the Investors section under calendar of events. The earnings press release and other financial data and information are available under Press Releases. With me this morning are John Fischer, Olin's Chairman, President and Chief Executive Officer; Pat Dawson, Executive Vice President and President, Epoxy and International; Jim Varilek, Executive Vice President and President, Chlor Alkali Products and Vinyls and Services; and Todd Slater, Vice President and Chief Financial Officer. Now, I'd like to turn the call over to John Fischer. John?

Thank you, Larry. Good morning and thank you for joining us today. During this morning's call, I will begin by highlighting the key takeaways from a successful 2018, review all-in solid performance in the fourth quarter and our forecast for 2019. I will finish with a more detailed discussion of each of our business segments and market dynamics. Now let's turn to slide three. As I mentioned, 2018 was a successful year for Olin. The company generated a record full year adjusted EBITDA of $1.265 billion, which represents a 34% increase over 2017 adjusted EBITDA. Adjusted EBITDA has grown 50% over the past two years. Driving the 2018 growth was the 35% improvement in Chlor Alkali Products and Vinyls adjusted EBITDA and an 88% increase in the Epoxy business adjusted EBITDA. Both businesses benefitted from double digit revenue growth during 2018. During the fourth quarter of 2018, we generated adjusted EBITDA of $301 million as we closed the year with strong December performances in our Chemical businesses. Utilizing the cash flow generated by the businesses, we acquired 1.6 million shares of stock during the quarter, raising the total shares repurchased during 2018 to 2.1 million. In addition, we were able to pay down $122 million of debt during the quarter, bringing our total debt repayments for the year to $376 million, which put the year-end net debt to EBITDA ratio at 2.4 times. We remain committed to a balanced approach to capital allocation, which includes ongoing deleveraging, investing in our businesses and returning cash to our shareholders. Now let's turn to slide four and discuss our outlook for 2019. For full year 2019, we expect adjusted EBITDA to be comparable to our record 2018 results. Looking at the forecast in more detail, during the fourth quarter and through January 2019,…

Thanks, John. Let's turn to our 2019 cash flow forecast, which is on slide 11. We expect to generate approximately $475 million of free cash flow in 2019, with a combination of debt reduction and EBITDA growth over last 12 months. As of year-end, our net debt-to-adjusted EBITDA leverage ratio has been reduced to 2.4 times. We are targeting $250 million to $300 million of additional debt prepayments in 2019. Starting with our full year adjusted EBITDA forecast, which is similar to 2018 levels on the far left of the waterfall chart, we deduct $90 million in estimated cash tax payments. We're forecasting that our cash tax rate will be in the 25% range for the year. Cash taxes in 2019 are expected to be higher than 2018 by approximately $40 million as Olin exhausted the tax credit carryfowards that were created with the 2015 acquisition during 2018. Column three reflects the midpoint of our current forecast for capital spending of $400 million, which includes annual maintenance capital spending of between $225 million and $275 million. The investment associated with our multiyear information technology integration project of approximately $80 million. As we've previously discussed in 2017, we began a multi-year project to implement new enterprise resource planning, manufacturing, and engineering systems across the heritage Olin and the acquired Dow Chlorine Products businesses. The project includes the required information technology infrastructure. Now, turning to column four, we're expecting working capital to be neither a use nor source of cash in 2019. In the next column, one-time items include information technology integration costs and cash restructuring cost of approximately $80 million. This includes approximately $40 million for the IT integration project that I just spoke about. And approximately $25 million of duplicate IT costs that are being incurred during the transition. The…

We will now begin the question-and-answer session. [Operator Instructions] And the first question comes from Neel Kumar with Morgan Stanley. Please go ahead with your question.

Hi. Good morning.

Good morning.

As a point of clarification, you mentioned using fourth quarter caustic prices in your guided, is that inclusive of the recent $20 decline in the domestic index in January?

No, it's not.

Okay. And do you know what roughly the impact that would have in terms of EBITDA for 2019?

Neel, this is Todd. What - when you look at the fourth quarter caustic soda pricing, and you annualize that for all of 2019, that's between $120 million and $150 million year-over-year headwinds to Olin. We've also said that the first quarter caustic soda pricing in our system will be down about 5% from the fourth quarter.

That's very helpful. And then in terms of the epoxy, it seems that pricing has come down, but raw material costs seem to have been coming down even further. So would it be accurate to say that you would expect the margin expansion in 2019 assuming current pricing for resins and ethyl cost?

I would say that's true if the relationship stays the same. And as we've seen over the last couple of years, raw material cost moved very dramatically and quickly. But I think if we were able to freeze everything where it is today we would get some margin expansion.

Okay, great. Thank you.

And our next question comes from Don Carson with Susquehanna. Please go ahead with your question.

Thank you. John, you've given your increased specific on your caustic outlook. Can you talk a bit about what you expect EDC pricing to be and also what your assumptions are for ethane costs?

In terms of our EDC pricing assumptions, we're assuming that it will be better throughout 2019 than it was in 2018. And we've assumed that ethane prices as we move forward are going to be in the $0.30 to $0.35 range.

Okay. And then on the caustic export market, volumes were pretty low as you've noted in Q4. Do you expect that weakness in offshore exports to continue? I guess two offsetting factors here obviously when Alunorte comes back online that will be positive, but are you anticipating some softness as some have projected in demand out of Australia this year, the U.S. Gulf Coast exports.

Hi, Don this is Jim Varilek. As far as the export volumes go you're right that fourth quarter was impacted and quite honestly exports have been impacted somewhat by the Alunorte outage as that was a direct export out of the U.S. And we do expect obviously if that gets all - as that get solved we'll have an increase in exports. Out of Australia, the alumina business as it continues to settle and improve. I think the end user demand, I think we'll see pretty steady demand and it's just a matter - out of Australia and it's just a matter of where it's sourced. I think that's the issue. But we would expect exports to continue to improve and we'll see a stronger export year this year than last year.

And just one final question, you gave a lot of clarity in terms of the earnings leverage with everything, but the exception of epoxy margins. Is that something you're going to provide us more detail on next week?

Not specifically, no.

Okay, thank you.

And our next question comes from Eric Petrie with Citi. Please go ahead with your question.

Hi. Good morning.

Good morning.

Todd as you noted, leveraged has improved to 2.4 times. What is your target there, and priorities for cash flow going forward?

In 2019, we expect to repay or prepay another $250 million to $300 million of debt. As you know we have a big payment at the end of 2020 associated with the ethylene of $450 million. If our forecast of the $1.26 billion-ish for 2019 is ultimately the final answer, that put you at 2.2 net debt to adjusted EBITDA at the end of 2019.

Thanks. My second question is, you noted that the $1.5 billion target was achievable in the near-term. Now you're guiding to roughly flat year-over-year compared to 2018? So how do you see the bridge for reaching that $1.5 billion and what are the puts and takes?

I would say it really represents two things. It represents a combination of volume growth and it represents some pricing growth. But I would say we see that that is achievable it can be done with the assets that we have on hand. And I would also just point out in a different pricing environment, which we had in the third quarter of 2018 we generated almost $400 million of EBITDA in one quarter, which obviously puts us on - would put on a path to generate $1.5 billion.

Great, thanks.

And our next question comes from Kevin McCarthy with Vertical Research Partners. Please go ahead with your question.

Yes, good morning thank you. A few questions on epoxy. First, can you comment on how much do you think global demand for epoxies grew in 2018? Any regional color related there too? And then second, on slide number eight you show some of the price changes, very high numbers in North America and Asia, about half of that amount in Europe. And so, could you comment on what is driving those regional differences in price?

Yes. Kevin, this is Pat. First of all from a demand standpoint, Asia and China has been very lackluster. I don't know that China really grew hardly at all, it's pretty flat year-over-year and I would say that's true for most of Asia. You saw a lot of reports coming out of China, specifically on automotive being down 30%. So, that part of the world was pretty depressed. I think Europe did not grow as much in 2018 as it did in 2017. I think Europe was relatively flat. North America was probably one of the better regions in 2018 and a lot of that was fueled by oil and gas being better. But overall, globally, Kevin, I would say the demand was pretty flat year-over-year. We are encouraged by what we're seeing here early in the first quarter with a big destock in Q4, but we are seeing demand levels around the globe come back to pretty much where they were in Q1 of last year. From a pricing standpoint on that question, Europe had very good gains. The European market was much tighter in 2017 than the way it evolved in the second half of 2018. So Europe simply started out with higher prices than 2017 and cooled off as 2018 progressed. So that's part of the reason on that percent difference. North America obviously was very consistent with the pricing improvements that we saw coming out of Asia Pacific and a lot of the Asian exports that find their way into North America and Europe. So we had very good pricing momentum quite frankly though throughout the whole year in all regions of the world.

And last question if I may. You made a comment in your prepared remarks, if I heard it correctly that chlor alkali could be sold out by 2021. Perhaps we'll hear more next week, but I was wondering if you could comment on the rates of demand and supply growth that you're basing that on?

I would prefer to leave that for next week because we're going to have a third party talk about that.

Okay, thank you very much.

And our next question comes from Jeff Zekauskas with JPMorgan. Please go ahead with your question.

Thanks very much. Your chlor alkali segment EBITDA was up I think $294 million in 2018. Is 90% of the EBITDA increased caustic soda? Can you do some kind of bridge as to the different part of the chlor alkali segment and how you got that $294 million increase?

The big driver of the just under $300 million, Jeff, is pricing. And it's really pricing across virtually every product we had. Obviously caustic soda was a big driver, but chlorine, EDC, chlorinated organics, HCL, bleach, all those prices were up year-over-year. And so, caustic is the one that gets a lot of headlines, but in fairness all contributed significantly to that just under $300 million earnings growth. Volume year-over-year was more flattish.

So you had to divide it up into percents, what percent came from caustic soda, what percent came from chlorine derivatives in rough terms of the increase?

The 90% would be too high. We have not broken out those numbers specifically publically.

Okay. I guess you don't plan, all right. In terms of tax rate for 2020, is it much different than tax rate in 2019 on a cash basis?

This is Todd again. The 25% is still a good number. That has a lot to do with the NOLs being utilized by the end of 2018. So 25% is still a good number.

Okay. And then lastly on your CapEx the $400 million includes $80 million of information technology costs. But I saw some of that passes through the income statement. So shouldn't the net number for CapEx as to what would be on the funds flow statement be lower than $400 million?

$80 million goes through capital. There is another $40 million associated with the project that runs through expense through those other one-time items.

So in other words, there is - okay, there is $80 million that goes through the cash flow statement and then an additional $40 million that goes through the income statement?

Yes. I mean, we've tried to help folks out with that and the investors. If you look on the slide deck today on slide 25, we've tried to identify all those costs expense and capital through the end of the project through 2020.

Okay, great. Thank you so much.

And our next question comes from Jim Sheehan with SunTrust. Please go ahead with your question.

Good morning. Gentlemen, if you could give us your best guess as to when the Alunorte operating rates will start to ramp up and they will start ordering more caustic soda from the U.S. Gulf?

Yes, Jim, this is Jim. I don't have a real good answer for you, but what I can say is that there is progress that's been - that are being made. The equivalent of the ETA has lifted the embargo to basically saying that the plant is safe to operate and we're just waiting for a national embargo to be lifted before the restart. So it could be weeks, but we are dealing with government so it still could be longer than that. We're hopeful that it happens in the first quarter.

Thank you. And then on working capital your outlook for flat working capital changes in 2019. Can you just provide your assumptions underlying that?

Yes, this is Todd, we - obviously we are saying caustic soda pricing will obviously improve over the year in order to get to the 2018 fourth quarter average. So there could be a little bit headwind in receivables. Having said that, we've also assumed hydrocarbon costs are lower. So you'll see a little bit of benefit on the other side, net-net we're expecting working capital to be flat.

Terrific, thank you very much.

And our next question comes from Matthew Blair with Tudor, Pickering, Holt. Please go ahead with your question.

Hey, good morning everyone.

Good morning.

Of the $400 million in CapEx for 2019, how much of that is growth versus maintenance? And are there any upcoming organic projects such as like another bleach plant that you'd like to highlight?

I think when you add in the IT project that Todd just talked about and another project related to integration and add that to growth - or add that to maintenance. The majority of the spending is in maintenance. I would also say that there are smaller growth projects like bleach plants, and bleach plant expansions, hydrochloric acid plants that are ongoing all the time. And I would tell you we will provide more guidance around what our objectives are around that next week.

Okay, thanks. And then, with the rig count coming down it looks like HCL prices have come off in January. I think on slide 16 you highlighted HCL is up pretty strong in the fourth quarter. Is there any way that you could ballpark either volumes or EBITDA contribution from this area?

What I would say is that prices have come from fourth quarter to first quarter, but not dramatically. And I would also tell you that our volume forecast for hydrochloric acid in 2019 are very similar to what we saw in 2018.

Okay, thank you.

And our next question comes from Mike Sison with KeyBanc. Please go ahead with your question.

Hey guys, nice quarter.

Thank you.

In terms of caustic aside Alunorte, there are eight other end markets that you need to see improvement as the year unfolds to tighten up supply to kind of get that pricing improvement?

Mike, this is Jim. I think generally what we need to see is that take some of the uncertainty out of the climate. We saw in the fourth quarter economic uncertainty, it wasn't just in chemicals, but across all of the industry. And so, I think that's something that we need to see diminish and we are, just quite honestly we are seeing things as we go into January we are seeing things pick up both here in the U.S. and also around the world. Another thing that will impact us in terms of the pricing is that there are a significant number of maintenance turnarounds and so forth that are scheduled in the first quarter. So the combination of improving demand and limited supply provide a better pricing environment as we go through the quarter.

Got it. And with you think about longer term and chlor alkali capacity doesn't - is minimal the next two to three years the demand is generally good. I don't want to state your thunder from next week, but where do you think profitability for the segment would be couple of years from now? And then at what point would it make sense for Olin to think about adding some capacity?

Well, I'll go back to one of the earlier questions that asked about $1.5 billion and say I think with the assets we have the combination of improved volumes, which would mean higher operating rates for Olin and some improved pricing. We can see clear to making $1.5 billion on that.

Got it, thank you.

Our next question comes from Vincent Anderson with Stifel. Please go ahead with your question.

Thank you. I want to talk about the spot market a bit. How comfortable are you right now with the depth of the spot market, given; one, where we are in the chlor alkali cycle and also given the volatility that we observed over the last few months. I mean, would you expect to shift more of your contracts towards shorter duration volume commitments or maybe take your lumps now by allocating more to spot to firm up bid spreads in your larger volume contracts that you're negotiating right now. Just trying to get a sense of how you're managing your book in this environment.

Vince, this is Jim. As far as contracts go the percentage of contracts this year is not going to be any different than last year. So we're not putting more or less into the spot market. The spot market has been trading in pretty thin quantities over the last - actually the last six or seven months. I think that stems from the early part of last year where supply was actually very tight. And so many of the customers contracted for high volumes and it made the spot market thin. And we saw that throughout the latter part of last year and we're seeing that again this year in January for example there was one spot barge domestic and two parcels on an export basis, which is a very thin export market. So it would indicate to me that there's still a lot of contracts out there and supply demand fundamentals are intact.

Great, thanks. And then how do you think about your acquisition pipeline right now along the chloride value chain. Are there any areas where procurement for instance might offer some low hanging synergies in this improving price environment for commodity chlorine.

I would say that we are not thinking about acquisition as it relates to our existing chlor alkali infrastructure. If you look at our position in North America from an antitrust perspective I don't believe there's anything out there that we could buy from a chlor alkali perspective.

Okay, thank you. And then if I could just ask one more clarification on Alunorte, without guessing as to the exact date of the restart they've said publicly that the ramp up would take some months. But when you think about its impact on the caustic market would you expect to see caustic benefits sooner as a rebuilding raw material working capital. Or is your intelligence kind of pointing to they had enough inventories still sitting around when they were shut down that you would really have to wait for a full return to higher percent utilization before it actually impacted caustic.

Yes, I think that - this is Jim. I think that you'll see advanced shipments of their restart obviously with lead times and that's an importing material then you'll know in advance of their start up. So it'll be positive before they actually startup and then building some inventory to be able to restart the plant.

All right, thanks so much.

And our next question comes from Mike Leithead with Barclays. Please go ahead with your question.

Good morning guys. Just one on capital deployment so you're guiding to roughly $475 million of free cash, $275 million of that sounds to be going at that pay down and roughly $130 million going at dividend, which leaves maybe only $70 million or so for buybacks. So I guess with net leverage now below your 2.5 times target EBITDA growing can you just talk about why further debt reduction is the top priority versus maybe a more aggressive share repurchase program here?

Yes, we will continue a balanced approach to capital allocation and we will continue to delever the balance sheet we had talked about 2.5 times was the target for the end of 2018. We have ultimately talked that we want to be at 2 times or under by the time we get to mid-cycle. So we still need a little bit of debt repurchase repayment to get there.

Fair enough and then just a quick housekeeping item what was the EBITDA tailwind from stock-based comp in the quarter?

We will have to get back to you on the answer to that question. Thank you, we will.

Thank you.

And our next question comes from Frank Mitsch from Premium Research. Please go ahead with your question.

Good morning folks. And John I really appreciate the teaser for the Investor Day next week in terms of the third party speaker I am going to start a betting poll as to who that might be. When you guys put out your 2018 guidance you bracketed plus or minus 5% if I were to take that number for 2019 that would get you to $1.2 billion to $1.33 billion is your thought that that is too broad of a range. How should we think about the range of outcomes around that the $1.265 billion guidance?

I think the reason we said it was balanced is because the majority of the upside and the downside has to do with caustic soda and that is obviously the product to which we have the most leverage. And we didn't really feel comfortable given where we are at this moment of actually trying to bracket it.

Fair enough. And I was just taking your comments here, I guess the way the math would work out is at least looking at the first quarter you're looking at something that will be up year-over-year, but probably down a little bit sequentially is that a fair read of the puts and takes?

Yes, it would be.

Thank you so much. See you next week.

Okay.

And our next question comes from John Roberts with UBS. Please go ahead with your question.

Thank you. It's not as bigger business as it used to be, but are there more restructuring opportunities you could have in Winchester to elevate it along the bottom here. When might you expect your first up year-over-year quarter in earnings for that business?

The answer to your first question is, yes, there is always things we can do in the business to make it better and I think we're continuing to do those things. I would expect that we will see an up quarter in the second half of 2019.

And then I'm kind of surprised it sounded like you expect your contract versus spot sales in 2019 to be roughly the same volume mix that you had in 2018. Why wouldn't customers be letting contracts just expire given we've got this really large premium they're paying over spot prices. And then they can come back and recontract next year and just let why aren't customers going more into the spot market to take advantage of the gap here?

Yes, John the comment that I made earlier was the market is actually pretty thin, so to go out there in large quantities and so forth with large volumes to get product is also is fairly difficult. And I believe that our customers understand the market pretty well and they see the fundamentals that we've been talking about for quite some time. So their job number one is to get security of supply; number two, to get it at the best pricing. So I think they're boating with their feet in terms of how they want to go about contract and so forth.

Thank you.

And our next question comes from Steve Byrne with Bank of America. Please go ahead with your question.

Yes, thank you. What portion of your chlorine production is allocated to the VCM tolling agreement with Dow for their Shintech [ph] contract?

We will provide guidance next week on - much more guidance on where our chlorine capacity goes next week.

Can you comment on your interest in locking that up longer term versus finding other molecules to move that chlorine into?

I think we announced about a year ago that we had already locked up the renewal of that contract. So beginning in 2021. That contract moves from a tolling arrangement with Olin supplying the chlorine to Dow again under the tolling arrangement to Olin selling BCM directly to Dow's current third party customer.

Okay. And how would you characterize the demand for caustic over the last year, any changes in that demand? Your customers may have sourced different feedstock such as bauxite for alumina that may have reduced global demand for caustic versus say 2017 levels before the run up in price?

Yes, this is Jim. What I would say is that there is always ups and downs and quarter-to-quarter variation in demand. What we look at is the long-term trend lines. And caustic demand moving more with consumables and so forth is going to be a steady drumbeat over a longer period of time. You do have the disruptions that we've already talked about between Bureau of Industry Standards or Alunorte or so forth. But as GDP clicks on, industrial production moves along and consumables continue to grow that's the way the caustic market is going to go. And so, that's what we would expect over the next several years to continue.

Okay, thank you.

And our next question comes from Arun Viswanathan with RBC Capital Markets. Please go ahead with your question.

Great, thanks. Good morning, guys. I have a couple of clarifications on the pricing and 2019 expectations. So it looks like you're expecting caustic prices to be down 5% in Q1 sequentially. And then you also made the statement on average 2019 pricing would be similar to 2018. So are you saying that your export end contract pricing on caustic to be similar in 2019 versus 2018? And if so, is the assumption that you've got the 5% decline in Q1 back in Q2 through Q4? And maybe you can just highlight the cadence of that with a price discovery [ph]? Thanks.

Let me clarify. We said that the - our assumption was that 2019 pricing will be equivalent to the fourth quarter of 2018 pricing. And the 5 - and that relates to domestic contract, export, spot, the whole shebang. Our 5% decline in Q1 versus Q4 was on our entire portfolio. And our statement that we expect it to recover throughout 2019 is also as it relates to our entire portfolio.

Okay, that's helpful. And then on the bridge to kind of - so on the bridge to flat EBITDA, I guess you did mention that epoxy could be higher on volume and potential hydrocarbon release. I guess what are you assuming for the other two, I guess Winchester, would you expect that conditions would be still relatively challenged and potentially worse or better in 2019. And then similarly caustic given that the pricing would be similar to Q4, would that be a little bit worse in 2019? And maybe you can just tie-in the comments on turnaround and anything else that's relevant there?

There are essentially four big points to our full year guidance. We expect caustic soda year-over-year to be lower. We expect the impact to that to be partially offset by improved pricing across chlorine and the chlorine derivatives. We expect epoxy to improve with better - slightly better volumes, lower hydrocarbon cost and lower turnaround cost because that's where the benefit of the turnaround cost will show up and we will have higher corporate costs. We have essentially assumed Winchester is flat.

Perfect, thank you. And then lastly if I may on the mid-cycle bridge, the $1.5 billion, I think you noted in the past that that included epoxy at about $250 million, Winchester at $125 million and the rest being chlor alkali. Is that still how you think about getting to that $1.5 billion or has that changed given the differences in the Winchester business and even caustic and epoxy maybe you can just bucket how you're looking at that $1.5 billion? Thanks.

As we said today, I would tell you that that $1.5 billion would not include a $125 million from Winchester. There will be increased profitability from the chemical side and lesser profitability from the Winchester side.

Understood. Thanks, John.

And our next question comes from Aleksey Yefremov with Nomura Instinet. Please go ahead with your question.

Good morning. Thank you for providing a lot of details around your guidance. Does the 5% quarter-over-quarter decline in caustic realization include the benefit of contract renegotiations, or should we think of contract negotiations offsetting that 5% in Q1?

It includes the benefit of contract negotiations.

And just as a follow-up. The timing of the benefit of contract renegotiations doesn't pretty much kick-in January 1. So we can assume you'll get sort of $10 million quarter-over-quarter pick-up from that or that's more ratably over the course of the year?

No. I think for modeling purposes as you can assume it's pretty much evenly across the quarters of the year.

And I'll quick one if I may. On chlorine you're assuming some pick-up in pricing in both Q1 and in 2019 on average. I think so far January chlorine contract has been flat. Are you assuming that the contract itself will go up or you have better discount similar to what you are experiencing in caustic?

Well, we did say in the remarks that the contract renegotiation benefit covered chlorine and caustic soda, so that's one point. Second, we've talked about better pricing across the chlorine derivative portfolio. So we've seen better pricing on - for example on bleach right now we're experiencing better year-over-year pricing on EDC and that all factors into what our comments were Aleksey.

Understood. Thank you, John.

And this concludes our question-and-answer session. I would like to turn the conference back over to John Fischer for any closing remarks.

Yes. So I'd like to thank you all for joining us today. And I hope to see you all next week in New York. So thank you very much.

The conference is now concluded. Thank you for attending today's presentation. You may now disconnect your lines.